Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615149 | 1.00 | TAAR1 (0.43) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20356318 | 1.00 | TAAR1 (0.43) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22001798 | 1.00 | TAAR1 (0.43) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19019941 | 0.91 | MMP3 (0.42) | NPC1RAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL17302707 | 0.86 | LTA4H (0.44) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12475908 | 0.86 | TAAR1 (0.49) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15674300 | 0.86 | TAAR1 (0.49) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19026404 | 0.86 | TAAR1 (0.49) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25854487 | 0.85 | LTA4H (0.43) | TAAR1LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22001712 | 0.83 | REN (0.40) | NPC1RAB9ASMN1; SMN2SPHK1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548986-B2 | Eribulin-based antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548986-B2 | Eribulin-based antibody-drug conjugates and methods of use | FOLR1, FOLR2, TUBB1 | TAAR1 2826/4885LTA4H 3728/4885NPC1 1708/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | TAAR1 2826/4885LTA4H 3728/4885NPC1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.